🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Hakim Mahammedi

Centre Jean Perrin

ORCID: 0000-0002-7596-2357

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial”.

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Cancer Cell(2020)10.1016/j.ccell.2020.08.007

N/A

4.8DataRank · unranked

398 citations

Russell K. Pachynski, Vivek Narayan, Aude Fléchon, Gwénaëlle Gravis, Matthew D. Galsky +10 more

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

The Lancet(2024)10.1016/s0140-6736(24)01653-2

N/A

4.3DataRank · unranked

287 citations

Daniel Castellano, Ken Herrmann, Johann S. De Bono, Neal D. Shore, Kim N. +18 more

Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

Annals of Oncology(2025)10.1016/j.annonc.2025.07.003

N/A

0.663DataRank · unranked

31 citations

K.N. Chi, Neal D. Shore, Ken Herrmann, Johann S. De Bono, Daniel Castellano +88 more